Halozyme Therapeutics HALO Return on invested capital

Return on invested capital at other companies

West Pharmaceutical ServicesWST

19.3%+1.4pp

AptarGroupATR

10.9%-0.5pp

Opko HealthOPK

-3.7%-1.6pp

Amneal Pharmaceuticals, Inc.AMRX

20.3%+10.3pp

Ionis PharmaceuticalsIONS

-80.3%+2,757pp

Arrowhead ResearchARWR

-38.8%+135pp

FAQ

What is Halozyme Therapeutics's return on invested capital?

Halozyme Therapeutics (HALO) reported return on invested capital of 34.1% in Q3 2025.

How has Halozyme Therapeutics's return on invested capital changed year-over-year?

Halozyme Therapeutics's return on invested capital increased by 45.8% year-over-year, from 23.4% to 34.1%.

What is the long-term trend for Halozyme Therapeutics's return on invested capital?

Over 4 years (2020 to 2024), Halozyme Therapeutics's return on invested capital has grown at a -7.6% compound annual growth rate (CAGR), from 36.7% to 26.8%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.